Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

HKEX Discloses Goldman Sachs Reduced Zai Lab Stake to 6.67%

CICC: Zai Labs Q1 Results In Line, Downgrades 2026-2027 Profit Forecasts and Target Prices

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Zai Lab Chairman Du Ying Sells $2.02M in ADS Shares, Holding Drops to 1.12 Million

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

Sunshine Pharmaceutical (01952): Non-executive Director Fu Wei spends approx 20.7M HKD to acquire 660k shares

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

Sichuan Kelun Biotech Obtains Approval to Begin Clinical Trials for PD-1xVEGF Bispecific Antibody SKB118

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Zai Lab's Drug Zoci Receives FDA Fast Track Designation for the Treatment of Extracranial Neuroendocrine Carcinoma

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

159892

512290

159837

159992

159316

159859

159849

159570

520500

United Laboratories has received clearance from China's NMPA to begin clinical trials for its innovative drug TUL108, a broad-spectrum beta-lactamase inhibitor aimed at treating bacterial infections. The drug will be tested in combination with meropenem against drug-resistant pathogens. The U.S. FDA had previously approved the investigational new drug application for TUL108 on January 28, 2026.

PUBT

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

UNITED LAB

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

United Labs says China regulator clears TUL108 injection for clinical trial

516930

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

ZLAB

09688

159929

562050

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

Zai Lab

ZAI LAB

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Hwabao WP CSI Pharmaceuticals ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

512010

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

E Fund CSI 300 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

TransThera reports promising tinengotinib results in advanced solid tumors

02359

Wuxi AppTec plans to raise approximately $1 billion through U.S. dollar-settled zero coupon convertible bonds to enhance its capacity and capabilities. The bonds, convertible to shares at an initial price of HK$153, represent about 9.1% of the enlarged H-share capital. The proceeds will be used for global expansion and corporate purposes. Morgan Stanley, Citigroup, and Goldman Sachs are advising on the issuance.

MorningStar

Morgan Stanley

Citigroup

Goldman Sachs

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds

603259

WUXI APPTEC plans to issue RMB6.78 billion in zero-coupon convertible bonds due 2027, with an initial conversion price of HKD153 per H share. This represents a 17.6% premium over the previous closing price. The bonds may convert into approximately 51.147 million H shares, accounting for about 9.11% of the enlarged H share capital. Estimated net proceeds are around USD1.023 billion, with 90% allocated for global expansion and 10% for general corporate purposes.

AASTOCKS News

First Trust NYSE Arca Biotech Index Fd

WUXI APPTEC  Plans to Issue RMB6.78B Convertible Bonds

02105

Laekna, Inc. has scheduled its annual general meeting for June 5, 2026, in Shanghai to seek shareholder approval for its 2025 audited financial statements, the re-election of directors, and to authorize share issuance up to 20% of its issued share capital. The company aims to enhance its capital flexibility for future growth. The latest analyst rating for Laekna's stock (HK:2105) is a Buy, with a price target of HK$24.16.

LAEKNA-B

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

BetterLife Pharma Inc. has appointed Doug Drysdale as Executive Chairman and Director. Drysdale, previously CEO of Cybin Inc., is recognized for his leadership in advancing mental healthcare. His appointment aims to enhance BetterLife's growth strategy, particularly in developing innovative therapies for neurological disorders. The company will grant him stock options for 3.5 million shares. BetterLife focuses on BETR-001, a non-hallucinogenic LSD derivative for treating neurological disorders, and is exploring further development opportunities for its drug candidate targeting viral infections.

StockTitan

Proshares UltraShort Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares US Pharma

VG Health

VanEck Biotech ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

SPDR S&P Health Equip

Proshares Ultra Nasdaq Biotech

Cybin

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director | BETRF Stock News

Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET | B Stock News

BlackRock, Inc.

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET | B Stock News

02509

WXXWY

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

QYUNS-B

WuXi Biologics

SKB BIO

WUXI BIO

TEDA BIOMEDICAL

INNOVENT BIO

WUXI XDC

ICBCCS SSE STAR Biology and Medicine ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)(520500.SH)

United Labs says China regulator clears TUL108 injection for clinical trial

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

STOCKS | Hong Kong's Innovative Drug Sector Declines

TransThera reports promising tinengotinib results in advanced solid tumors

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds